RBC Capital Keeps Their Hold Rating on BioCryst (BCRX)
RBC Capital analyst Brian Abrahams maintained a Hold rating on BioCryst (BCRX) today and set a price target of $5.00. The company’s shares closed last Monday at $4.97.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 13.0% and a 55.5% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Proteostasis Therapeutics, and Intra-Cellular Therapies.
BioCryst has an analyst consensus of Moderate Buy, with a price target consensus of $8.50.
See today’s analyst top recommended stocks >>
Based on BioCryst’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.82 million and GAAP net loss of $37.6 million. In comparison, last year the company earned revenue of $5.89 million and had a GAAP net loss of $31.05 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.